Invitation: Sobi's Q1 report

Invitation: Sobi's Q1 report. Swedish Orphan Biovitrum AB Sweden

before the conference call.

To participate in the conference call, please use the following dial-in details:
Sweden: [phone]
United Kingdom: [phone]
United States: [phone]
For other countries, please find the details here.

Sobi

Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q1-report,c4121777

The following files are available for download:

https://mb.cision.com/Main/14266/4121777/3332535.pdf

Invitation Sobis Q1 report

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-q1-report-302428777.html